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Abstract 
 This report examines the synthesis of new ligands based upon dipyrazolylmethane and 
diindazolylmethane. The goal of these modifications is to increase the acidity of the proton on 
the methyl carbon to allow for deprotonation. The ligands synthesized were 
dipyrazolylphenylmethane and diindazolylphenylmethane, as well as modifications of the latter. 
The products were analyzed by NMR spectroscopy and one crystal structure was obtained of 
diindazolylphenylmethane. 
  
1. Introduction 
 BODIPY compounds are based upon modification of a 4,4- difluoro-4-bora-3a,4a-diaza-s-
indacene core (Figure 1).1 The molecules have a variety of uses ranging from biomolecular 
labels2 to photodynamic therapy due to their fluorescence.3 Much research has been 
performed based upon modifying the BODIPY core to achieve desirable properties. 
 
 
 
Figure 1: BODIPY core (left), dipyrazolylmethane (center), diindazolylmethane (right). 
 There are many derivatives of the BODIPY core molecule, however nearly all use the 
pyrrole based core as opposed to the pyrazole based core.2 Some work has been done on a 
pyrazole analog.4 This report seeks to expand on this research by synthesizing modified versions 
of the dipyrazolylmethane synthesized previously. Of most interest in this project is 
modifications of the diindazolylmethane in order to increase the acidity of protons on the 
methane carbon. These modifications include addition of phenyl groups to the methane carbon 
to increase the stability of the carbanion intermediate. 
2. Experimental 
 General Information: All reagents and starting materials were purchased from 
commercial vendors and used without further purification. NMR spectra were recorded on a 
300 MHz spectrometer, chemical shifts were given in ppm relative to residual solvent 
resonances (1H NMR spectra). X-ray data were collected from a Bruker CCD-based 
diffractometer with dual Cu/Mo microfocus optics.  
Attempted synthesis of dipyrazolylphenylmethane (1) 
 A mixture of 2 equivalents of pyrazole (0.200 g, 2.94 mmol) and 10 equivalents of benzyl 
chloride (2.365 g, 18.68 mmol) were mixed in toluene with NBuHSO4 (50. mg) and NaOH (5.00 
g) in 5 mL water and refluxed for 24 hours. The desired product was not able to be isolated.  
Attempted alternative synthesis of dipyrazolylphenylmethane (1) 
 A mixture of 2 equivalents of pyrazole (0.895 g, 13.1 mmol), 1 equivalent of 
benzaldehyde dimethyl acetal (1.000 g, 6.571 mmol), and 1/20 equivalents of p-toluenesulfonic 
acid were refluxed in toluene using a Dean-Stark apparatus according to a literature synthesis.5 
The desired product was not able to be isolated. 
Synthesis of diindazolylphenylmethane (2) 
 A mixture of 2 equivalents of indazole (2.000 g, 16.90 mmol), 1 equivalent of 
benzaldehyde (0.898 g, 8.46 mmol), 1/20 equivalents of zinc chloride (0.0576 g), and 5 Å 
molecular sieves were refluxed for 24 hours in dichloromethane. The solution was filtered and 
allowed to evaporate. Crystals were obtained and characterized by NMR and X-ray 
crystallography (Figures 2, 3). NMR spectrum and X-ray data were obtained by Briana Schrage. 
1H NMR (CDCl3, ppm) 7.15 (4 H), 7.40 (5 H), 7.55 (2 H), 7.72 (2 H), 8.11 (2 H), 8.53 (1 H). 
 
 
Synthesis of diindazolylperfluorophenylmethane (3) 
 A mixture of 2 equivalents of indazole (2.000 g, 16.9 mmol), 1 equivalent of 
perfluorobenzaldehyde (1.660 g, 8.467 mmol), 1/20 equivalents of zinc chloride (0.0576 g), and 
5 Å molecular sieves were refluxed for 24 hours in dichloromethane. The solution was filtered 
and allowed to evaporate. Characterization showed a mixture of starting materials suggesting 
the synthesis was unsuccessful.  
Synthesis of diindazolyl-p-chlorophenylmethane (4) 
 A mixture of 2 equivalents of indazole (0.200 g, 1.69 mmol), 1 equivalent of p-
chlorobenzaldehyde (0.119 g, 0.847 mmol), 1/20 equivalents of zinc chloride (5.8 mg), and 5 Å 
molecular sieves were refluxed for 24 hours in dichloromethane. The solution was filtered and 
allowed to evaporate. Characterization showed a mixture of starting materials and desired 
product. Further purification is required to isolate the desired product. 
3. Results and Discussion 
 A total of five syntheses were attempted in this experiment. These were the syntheses 
of dipyrazolylphenylmethane from benzyl chloride as well as from benzaldehyde dimethyl 
acetal (Schemes 1, 2), diindazolylphenylmethane (Scheme 3), 
diindazolylperfluorophenylmethane (Scheme 4), and diindazolyl-p-chlorophenylmethane 
(Scheme 5). 
 
 
  
  
 
 
Scheme 1: Synthesis of 1, pyrazole (left), benzyl chloride (middle), dipyrazolylphenylmethane 
(right). 
 
 
 
 
Scheme 2: Synthesis of 1, pyrazole (left), benzaldehyde dimethyl acetal (center), 
dipyrazolylphenylmethane (right). 
 
 
 
Scheme 3: Synthesis of 2, indazole (left), benzaldehyde (center), diindazolylphenylmethane 
(right). 
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Scheme 4: Synthesis of 3, indazole (left), perfluorobenzaldehyde (center), 
diindazolylperfluorophenylmethane (right). 
 
 
 
 
Scheme 5: Synthesis of 4, indazole (left), p-chlorobenzaldehyde (center), diindazolyl-p-
chlorophenylmethane (right). 
 The syntheses performed in this report achieved a range of success. The reactions 
attempted with pyrazole were not isolated in this experiment, although 2 has been previously 
reported.5 One potential reason for the inability to isolate this compound may be due to limited 
reaction time, thus preventing the reaction from running to completion. The indazole based 
reactions saw more success, including isolation of 2 and potentially isolation of 4. The reason 
for the lack of characterization and further purification of 4 was due to lack of time to continue 
the experiment. Further experimentation is required to isolate and fully characterize this 
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compound. Interestingly, despite a similar reaction mechanism to synthesis of 2, compound 3 
was unable to be obtained, and characterization revealed only starting materials.  
 Compound 2 was characterized by 1H NMR and X-ray crystallography in Figures 2 and 3. 
The solvent used for the NMR spectra was CDCl3. These suggest that the synthesis and isolation 
of 2 was successful. The crystal structure of this compound has not been previously recorded.5  
 Further research can be performed to attempt complexation of the isolated compound 
with metals or BF3. Deprotonation could also be attempted through reaction with a strong base 
which is not a nucleophile. Finally, more modifications of the dipyrazolylmethane and 
diindazolylmethane ligands could be synthesized, which potentially could increase acidity of the 
methyl proton(s). 
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Figure 2: 1H NMR spectrum of 2. CDCl3 was used as the solvent. 
  
  
 
 
 
 
 
 
Figure 3: X-ray crystal structure obtained of compound 2. Table 1 contains data and parameters 
regarding the measurement. Hydrogen atoms omitted for clarity. 
  
 Compound Bisindazole_benzaldehyde 
Emp. form C21H16N4 
Form. weight 324.38 
Crystal system monoclinic 
Space group P21/n 
a/ Å 10.297(11) 
b/ Å 12.315(14) 
c/ Å 13.049(14) 
α(°) 90 
β(°) 101.703(15) 
γ(°) 90 
Volume (Å3) 1620.00(5) 
Z 4 
Dc (Mg/m3) 1.330 
µ (mm-1) 0.081 
F(000) 680 
Reflections collected 16370 
Data/Restraints/Parameters 4014 / 0 / 226 
GOF on F2 1.035 
R1 (on Fo
2, I > 2σ(I)) 0.0490 
wR2 (on Fo
2, I > 2σ(I)) 0.1054 
R1 (all data) 0.0747 
wR2 (all data) 0.1180 
 
Table 1: X-ray data collection and structure parameters for compound 2. 
  
4. Conclusions 
 Pyrazole and indazole based compounds were used to create a modified BODIPY core. 
The pyrazole based compound (1) could not be isolated. More success was found with the 
indazole based compounds, including characterization by NMR and X-ray crystallography of 
compound 2. Synthesis of 3 was unsuccessful, and 4 achieved mixed results and requires more 
experimentation. Further research is required to attempt deprotonation and complexation of 
these compounds. 
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Appendix 1 
Safety Considerations 
 Proper safety guidelines were observed at all times in the lab. This includes wearing 
proper PPE (Personal Protective Equipment) as well as following any and all additional rules set 
by Dr. Ziegler. PPE worn in the lab includes eye protection and gloves. Additionally, long pants 
and closed toe shoes were to be worn at all times in the lab. No reagents were to be removed 
from the lab at any time. All reactions took place inside of a fume hood. 
